P-0240 Long-Term Bevacizumab Treatment in Patients with Metastatic Colorectal Cancer who are Receiving FOLFOX4 and Folfiri Chemotherapy

Abstract

ABSTRACT Introduction This study assessed the efficacy and safety of long-term bevacizumab in combination with FOLFOX 4 and FOLFIRI chemotherapy regimens commonly used in the treatment of metastatic colorectal cancer. Methods Seventeen patients with metastatic colorectal cancer were enrolled in the study; 33% female and 67% male, medial age of 54 years, received combined chemotherapy of FOLFOX4 and bevacizumab 5mg/kg in first line setting each 14 days till disease progression determined. After disease progression patients followed on the same dose bevacizumab in combination with a second line FOLFIRI chemotherapy. Patients with complete (CR) and partial (PR) response or stable disease (SD) after chemotherapy (FOLFOX 4, FOLFIRI) completion proceeded on the same bevacizumab regimen. Primary endpoints were progression-free survival (PFS), overall survival (OS), overall response rate (ORR), disease control rate (DCR). Results In the first line FOLFOX 4+bevacizumab results were as follows: PFS median 11.3 months, ORR-58%, DCR-35.2%. In the second line FOLFIRI+bevacizumab: PFS median 10.7 months, ORR-29.4%, DCR-58%. Most common grade 3/4 adverse events (AEs) were neutropenia (FOLFOX 4 - 22%, FOLFIRI -26%). Also peripheral sensory neuropathy grade 2 appeared in 65% of patients who received FOLFOX 4. OS was 28.7 month and 12 patients still alive. No patient's treatment discontinuation from study was performed due to those AEs. Conclusions The results of this observational study with limited number of patients enrolled suggest that long-term bevacizumab treatment on FOLFOX 4 followed by FOLFIRI scheme improves therapy results and prolongs overall survival in metastatic colorectal cancer patients.